Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression

SHANGHAI, March 31, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater ...

2021-03-31 10:27 3248

Menarini Silicon Biosystems launches CELLSEARCH® Circulating Multiple Myeloma Cells Assay, a new non-invasive test to monitor disease status in clinical research studies

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., March 31, 2021 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today the launch of a new assay to meet the needs of pharma companies, CROs, clinicians and research scientists working on mult...

2021-03-31 10:00 4459

Viva Biotech Announced 2020 Annual Results

The Group's Revenue Surged by 115.7% YoY Revenue from the CFS Business Increased Significantly by 146.3% YoY Establish One-stop Service Platform for Novel Drug Discovery and Production via Internal Growth and External Expansion Financial Highlights of the year ended December 31, 2020: * Reve...

2021-03-31 07:03 3174

European Commission Approves mAbxience's Bevacizumab For The Treatment Of Certain Types Of Cancer

mAbxience, a global fully-fledged biotech company, with over a decade of experience in the development, manufacture and commercialization of biopharmaceuticals, is expanding patient access to biological treatments throughoutEurope. MADRID, March 31, 2021 /PRNewswire/ -- On 31 March 2021, the Eur...

2021-03-31 05:30 10219

Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing

WETTEREN, Belgium, March 31, 2021 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a manufacturing agreement expansion with AstraZeneca to include drug product manufact...

2021-03-31 01:04 1329

GemVax's highly promising Phase II Alzheimer's disease clinical trial results targeting telomerase published in prestigious Alzheimer's Research & Therapy' journal

SEOUL, South Korea, March 30, 2021 /PRNewswire/ -- GemVax & KAEL Co., Ltd. (Korea: 082270)("GemVax") has announced that a paper on GV1001, a novel Alzheimer's treatment based on telomerase modification, was published onMarch 26 th in the SCI-grade international journal 'Alzheimer's Research & Ther...

2021-03-30 19:21 1842

Ascletis Announces Investment Escalation in R&D of Cancer Lipid Metabolism and Oral Checkpoint Inhibitors

* Proposed Initiation of a Pivotal Phase II Trial of ASC40 in Combination with Bevacizumab in Chinese Patients with First Relapse of High-grade Astrocytoma * In-house discovered oral PD-L1 inhibitors demonstrated favorable anti-tumor activities in the animal model compared to a marketed anti-...

2021-03-30 08:00 3160

Ascletis Announces Investment Escalation in R&D of Cancer Lipid Metabolism and Oral Checkpoint Inhibitors

Novel Phenomics NASH In Vitro Assay Presented by InSphero AG and PharmaNest Inc at 2021 Society of Toxicology Meeting

Introduction of key technology to accelerate NASH drug discovery by combining 3D disease models and automated AI-based fibrosis quantification PRINCETON, New Jersey, March 30, 2021 /PRNewswire/ -- During the 2021 Society of Toxicology (SOT) Annual Meeting, researchers from Swiss-based InSphero AG...

2021-03-30 05:20 1141

Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round

CINCINNATI, March 30, 2021 /PRNewswire/ -- Amplicore Inc., an early-stage biopharmaceutical company currently developing locally delivered and minimally invasive therapeutic solutions for musculoskeletal diseases, has successfully closed its Series Seed round of funding at$4 million. Investments ...

2021-03-30 02:55 1215

Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round

Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company

SYDNEY, March 29, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd (Simcere) (HKSE: 2096) to develop and commercialise...

2021-03-29 17:43 3440

Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company's COVID-19 Vaccine Candidate

NEW BRUNSWICK, N.J., March 29, 2021 /PRNewswire/ -- Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vaccine Acquisition Task Team (AVATT) to make available up to 220 million dos...

2021-03-29 16:07 4483

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint

SHANGHAI, March 29, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Phase 2 study of its innovative PD-1 inhibitor HLX10 in patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumors that fail t...

2021-03-29 08:27 3667

Making Most out of Launched Products Fueling Diversified Innovation through Integrated Platform

SHANGHAI, March 28, 2021 /PRNewswire/ -- Henlius (2696.HK) announced the financial results for the year ended31 December 2020. 2020 marked a meaningful year for Henlius as the Company gathered the pace in commercialization and continued the momentum for innovation. The Company delivered a total r...

2021-03-28 11:16 2624

Genscript Biotech Reports Full Year 2020 Financial Results

Highlights: * Revenue of the Group for the year ended December 31, 2020 was approximately US$390.8 million, representing an increase of 42.9% as compared with approximatelyUS$273.4 million for the year ended December 31, 2019 * Gross profit of the Group for the year ended December 31, 2...

2021-03-27 02:16 6159

Modern Chinese Medicine Announces Year 2020 Annual Results

Solid growth with focus to broaden the distribution network and raise R&D efforts PERFORMANCE HIGHLIGHTS * The Group posted a consolidated revenue of approximately RMB308.7 million for the year ended31 December 2020, representing an increase of approximately 41.1%. * For the year ended 31 D...

2021-03-26 22:08 11894

Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years

BAGSVÆRD, Denmark, March 26, 2021 /PRNewswire/ -- Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment of obesity in adolescents aged 12–17 years...

2021-03-26 21:31 3542

Airway Therapeutics Announces FDA Acceptance of IND for AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)

Initiating Phase 1b randomized clinical trial with initial results expected in late 2021 Potential for novel, preventive AT-100 to reduce incidence and severity of serious respiratory disease BPD, improving outcomes and survival in very preterm infants CINCINNATI, March 26, 2021 /PRNewswire/ --...

2021-03-26 16:00 2123

Ascentage Pharma Announces Publication of Preclinical Data in Nature Immunology Showing Enhanced T-Cell-Mediated Antitumor Immunity Induced by Its MDM2-p53 Inhibitor APG-115

SUZHOU, China and ROCKVILLE, Md., March 26, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced the peer-reviewed publicati...

2021-03-26 08:38 1824

Antengene Announces Financial Results for Full Year 2020

SHANGHAI and HONG KONG, March 26, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" or "the company", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in h...

2021-03-26 08:00 3324

Chime Biologics Announced the Completion of US$190 Million Series A+ Financing to Accelerate Capacity Expansion

WUHAN, China, March 26, 2021 /PRNewswire/ -- Chime Biologics, a China-based, world-class CDMO company, announced today that it has secured a total commitment ofUS$190 million investment from institutional investors, and over $100 million investment has already been closed today. This round of fin...

2021-03-26 08:00 3459

Chime Biologics Announced the Completion of US$190 Million Series A+ Financing to Accelerate Capacity Expansion

1 ... 123 124 125126127 128 129 ... 181